Markets

Teva Pharmaceutical Industries Receives FDA Approval For DEGEVMA To Treat Bone Complications In Patients With Advanced Cancer

Sep 28, 2026 · 04:01 PM ET· updated 1h ago

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved DEGEVMA™ (denosumab-adet) as a biosimilar to Xgeva® (denosumab). DEGEVMA is

Why It Matters

Teva got permission to sell a new medicine for cancer patients. When companies get new medicine approvals, it shows they're growing and making money.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

TEVA38.75

-0.45 (-1.14%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.